Longitudinal 18F-FDG micro-PET/CT imaging (Fig 3A) was performed during endocrine therapy for ER+ breast cancer in ZR-75-1 xenografts since 18F-FDG is routinely used to follow cancer response to therapy. This evidence concerns the gene ESR1 and breast cancer.